Flunisolide nasal spray in the treatment of perennial rhinitis.
Twenty patients with perennial rhinitis took part in a double-blind, randomized, cross-over comparison of flunisolide nasal spray (Syntaris; Syntex) and its vehicle. The sprays were used twice daily for 4 weeks and a total daily dose of 200 micrograms flunisolide was used. Flunisolide was superior to the placebo in relieving sneezing, runny nose and nose-blowing (P less than 0,05). Patient and doctor treatment preferences were significantly in favour of the active spray. Side-effects were mainly confined to nasal irritation and occurred equally in both treatment groups.
D000281:Administration, Intranasal; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005446:Fluocinolone Acetonide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D012220:Rhinitis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D005446:Fluocinolone Acetonide; C007734:flunisolide